Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10028925 | BIONPHARMA | Liquid dosage forms of sodium naproxen |
Mar, 2026
(1 year, 10 months from now) | |
US10022344 | BIONPHARMA | Liquid dosage forms of sodium naproxen |
Mar, 2026
(1 year, 10 months from now) | |
US9693979 | BIONPHARMA | Liquid dosage forms of sodium naproxen |
Mar, 2026
(1 year, 10 months from now) | |
US9693978 | BIONPHARMA | Solvent system for enhancing the solubility of pharmaceutical agents |
Mar, 2026
(1 year, 10 months from now) | |
US11090280 | BIONPHARMA | Liquid dosage forms of sodium naproxen |
Mar, 2026
(1 year, 10 months from now) |
Naproxen Sodium is owned by Bionpharma.
Naproxen Sodium contains Naproxen Sodium.
Naproxen Sodium has a total of 5 drug patents out of which 0 drug patents have expired.
Naproxen Sodium was authorised for market use on 17 February, 2006.
Naproxen Sodium is available in capsule;oral dosage forms.
Naproxen Sodium can be used as temporary reduction of fever.
The generics of Naproxen Sodium are possible to be released after 03 March, 2026.
Drugs and Companies using NAPROXEN SODIUM ingredient
Market Authorisation Date: 17 February, 2006
Treatment: Temporary reduction of fever
Dosage: CAPSULE;ORAL